NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

人乳寡糖 (HMO)的全球市场:2020~2027年

Global Human Milk Oligosaccharides Market - 2021-2028

出版商 DataM Intelligence 商品编码 991630
出版日期 内容资讯 英文 180 Pages
商品交期: 约2个工作天内
价格
人乳寡糖 (HMO)的全球市场:2020~2027年 Global Human Milk Oligosaccharides Market - 2021-2028
出版日期: 2021年07月05日内容资讯: 英文 180 Pages
简介

人乳寡糖(HMO),是在母乳中存在的复杂的生理活性糖分子。可作为特定的有益细菌的成长基材。由于结构性多样复杂,制剂使用上难以合成或提取。人乳寡糖(HMO)产品,为了获得少量的HMO需要合成大量的母乳,耗费成本。因此,作为解决的办法,合成及开采技术提高。

本报告提供全球人乳寡糖 (HMO) 市场相关调查分析,市场概要,市场成长的影响要素,各市场区隔、各地区的市场规模和与前一年同期比较成长,及主要企业等相关分析。

目录

第1章 全球人乳寡糖 (HMO) 市场:调查范围、手法

  • 调查手法
  • 调查目的、范围

第2章 全球人乳寡糖 (HMO) 市场:市场定义、概要

第3章 全球人乳寡糖 (HMO) 市场:摘要整理

  • 市场明细:各应用领域
  • 市场明细:各地区

第4章 全球人乳寡糖 (HMO) 市场:市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 影响分析

第5章 全球人乳寡糖 (HMO) 市场:产业分析

  • 波特的五力分析
  • 供应链分析
  • 价值链分析
  • PEST分析
  • 价格分析
  • 法规分析
  • 偿付分析
  • 未满足需求
  • 专利趋势

第6章 全球人乳寡糖 (HMO) 市场:COVID-19分析

  • 市场上Covid-19分析
    • COVID-19前的市场情境
    • 目前市场情境
    • COVID-19后或未来情境
  • Covid-19期间中的价格动态
  • 需求与供给的频谱
  • 大流行期间中的市场相关的政府举措
  • 制造商策略性举措
  • 结论

第7章 全球人乳寡糖 (HMO) 市场:各应用领域

  • 简介
  • 市场规模分析及与前一年同期比较成长分析(%):各应用领域
  • 市场魅力指数:各应用领域
    • 婴幼儿配方奶粉
    • 机能性食品及饮料
    • 营养补充品

第8章 全球人乳寡糖 (HMO) 市场:各地区

  • 简介
    • 市场规模分析及与前一年同期比较成长分析(%):各地区
    • 市场魅力指数:各地区
  • 北美
    • 简介
    • 主要地区具体动态
    • 市场规模分析及与前一年同期比较成长分析(%):各应用领域
    • 市场规模分析及与前一年同期比较成长分析(%):各最终用途
    • 市场规模分析及与前一年同期比较成长分析(%):各国
  • 欧洲
  • 南美
  • 亚太地区
  • 中东、非洲

第9章 全球人乳寡糖 (HMO) 市场:竞争情形

  • 竞争模式
  • 市场定位/占有率分析
  • 合并和收购分析

第10章 企业简介

  • BASF SE
    • 企业概要
    • 产品系列、说明
    • 主要的焦点
    • 财务概要
  • Inbiose NV
  • Elicityl S.A.
  • Jennewein Biotechnologie GmbH
  • Glycom A/S
  • Medolac Laboratories
  • ZuChem Inc
  • Glycosyn LL
  • Shanghai Biochemical Co., Ltd.
  • Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
  • Beijing Solarbio Science & Technology Co., Ltd.
  • Anhui Elite Industrial Co., Ltd.,

第11章 全球人乳寡糖 (HMO) 市场:重要考察

第12章 全球人乳寡糖 (HMO) 市场:DataM

  • 附录
  • 关于本公司、服务
  • 咨询方式

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: DMFB3101

Market Overview

Human milk oligosaccharides (HMO) are present in human milk in the form of a complex bioactive sugar molecule. HMOs are growth substrates for certain useful bacteria. Extracting or synthesizing HMO in the formula is quite difficult as they are structurally diverse and complex. The human milk oligosaccharides (HMO) products available in the market are quite expensive as a huge quantity of human milk is synthesized just to obtain a small amount of HMO. Increasing concerns among consumers regarding gut health and the growing consumption of dietary supplements are expected to drive the growth. The global human milk oligosaccharides market valued USD XX million in 2020 and is forecasted to reach USD XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028)

Market Dynamics

Increasing demand for infant nutrition products

In the recent past, infant formula ingredients such as human milk oligosaccharides have become popular as an ingredient in the infant formula to meet the demands of the baby nutrition segment. Health benefits associated with the consumption of human milk oligosaccharides include maintaining gut microbiota and inhibition of pathogen in infants. China accounts for 30% of the global consumption of Infant formula which is followed by other Asian countries holding 28% of the market. About 65% of the growth in Infant formula market comes from China. In the United States, the HMO's intended for use in food other than dietary supplements are regulated under GRAS. In U.S CARE4U™ by DuPont was approved as GRAS, for use in infant formula and toddler foods. With the increasing demand for HMOs, in 2018, two HMO's have gone through the novel food safety assessment in Europe, with a positive assessment outcome and approval by the European Commission. In addition, due to the prebiotic functions and the antimicrobial protection of HMOs, they are increasingly used as a useful ingredient in products such as medicinal food, pharmaceutical, and infant formulas, thus driving the growth of the human milk oligosaccharides (HMO) market.

However, high cost associated with HMO products is expected to act as a restraint for the market growth. For example, expensive substrates such as glycosyl transferases require enzyme synthesis and this is one of the main factors attributable to the high pricing of human milk oligosaccharides. Prebiotics in infant formula, such as fructooligosaccharides and galactooligosaccharides, are used to inhibit the development of pathogenic Escherichia coli. Consumption of these has been shown to improve the health of infants' gastrointestinal tracts by promoting the development of specific microorganisms in the intestinal microflora. Owing to their low cost and wide availability, these are being used as a replacement for human milk oligosaccharides by infant formula manufacturers. As a result, these functionally equivalent alternatives to human milk oligosaccharides are severely limiting the overall market's expansion.

Market Segmentation

3'-Fucosyllactose (3'FL) is expected to dominate the global human milk oligosaccharides (HMO) market by product segment

3' FL plays an important role in the development of gut microbiota in both adults and infants. The Nestle Nutrition Institute, in a study, stated that HMO concentrations change during different stages of lactation with different types showing different dynamics. Products such as 6'SL or LNT decrease more rapidly within the first weeks of lactation, although, for example, 2'FL and 3'SL decrease more slowly over a longer period of time and again others, such as 3FL, actually increase concentration with time of lactation. In November 2019, DuPont Nutrition & Biosciences applied for a patent for the use of 3'-FL as a novel food.

2'-Fucosyllactose is poised to grow with the fastest CAGR of XX% in the forecast period 2021-2028 as dietary supplement manufacturers shift to 2'-Fucosyllactose, since it is capable of altering gut microbiota composition and behavior from formula-powered infants receiving additional feeding, and its contribution to healthy digestion.

Geographical Penetration

North America is the largest market for human milk oligosaccharides with a share of nearly XX% in global sales value in 2020

By geography, North America is expected to dominate the human milk oligosaccharides (HMO) market. North America has registered increased demand for donor human milk. On the other hand, there exist only 11 milk banks in countries such as Canada and the U.S., which is actually not sufficient to meet the increasing demand for donor milk. This factor will increase the usage of HMO in the infant formula in order to provide proper nutrition to the babies.

Asia Pacific is expected to grow with a CAGR of XX% during the forecast period. According to the WHO, in the next 10 years, the overall world population is expected to rise by about one billion and reach 9.5 billion by 2050. The constantly growing population is likely to increase demand for infant nutrition products in the Asia Pacific especially in countries like China and India owing to the high infant population. Moreover, rising concerns regarding gut diseases, high blood pressure, diabetes, and rickets among other chronic diseases have resulted in an increased demand for functional food and beverages, which is expected to propel the regional demand for human milk oligosaccharides.

Competitive Landscape:

The global human milk oligosaccharides (HMO) market is fragmented. The most active companies across the globe are BASF Corporation, DuPont Nutrition, and Health, ZuChem Inc. and Jennewein Biotechnologie GmbH among others. They have been expanding their geographical presence by acquiring or merging with the manufacturers in the foreign market. For instance, in February 2019, Jennewein Biotechnologie GmbH, a Germany-based functional sugars manufacturer, partnered with Yili.Com Inc., a China-based dairy products manufacturer, to research on infant microbiome and human milk oligosaccharides. This strategy was intended to develop innovative, HMO-based infant formula and was targeted at customers in China. Such developments/strategies are likely to surface over the forecast period, given the rising competition in the market. In May 2019, Glycosyn LLC and BASF SE signed an agreement for the development and commercialization of HMOs for widespread use in dietary supplements, functional nutrition, and medical food. As part of the collaboration and under the exclusive license, BASF SE will extend its offering of the most abundant HMO, 2'-Fucosyllactose (2'-FL) branded PREBILACTM, to emerging markets.

COVID-19 Impact: The market witnessed a positive impact owing to increasing demand for dietary supplements

A robust and diverse food supply is an essential part of the health and nutrition response to COVID-19. The demand for nutraceuticals & functional foods is expected to witness an upward surge owing to consumers opting for immunity boosting supplements during the COVID-19 pandemic. The use of HMOs in dietary supplements offer benefits such as immune support, protection against bacterial and viral infections, digestive comfort, and brain function support. Furthermore, a decline in the consumption of poultry, meat and seafood products across the globe is expected to increase the demand for plant and animal-based protein supplements in the near future.

Why Purchase the Report?

  • Understand the current market scenario and viability of global human milk oligosaccharides over the forecast period.
  • Visualize the composition of the global human milk oligosaccharides market in terms of product, type, and application to identify major players, growth potential, and market strategies
  • Identify the key regulations prevailing in the market and understand their impact on the market over the forecast period
  • Understand the key business factors such as market competition, product pricing, new product developments, and patent filings pertaining in the market

What we offer?

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Excel data sheet with valuable data points of the global human milk oligosaccharides market - Regional and Country level segmentation
  • Product mapping in excel for the key products of all major market players
  • Market Share Analysis covering business revenues ($) and revenue share (%) of key market players

Target Audience:

  • Human Milk Oligosaccharides (HMO) Manufacturers
  • Infant Formula Products Manufacturers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals

Table of Contents

1. Global Human Milk Oligosaccharides Market -Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Global Human Milk Oligosaccharides Market -Key Trends and Developments

3. Global Human Milk Oligosaccharides Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by Application

4. Global Human Milk Oligosaccharides Market - Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing demand for infant nutrition products
      • 4.1.1.2. The surge in the number of working mothers
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with products
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Global Human Milk Oligosaccharides Market - Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. Global Human Milk Oligosaccharides Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. Global Human Milk Oligosaccharides Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product segment
    • 7.1.2. Market attractiveness index, By Product segment
  • 7.2. Lacto-N-neotetraose (LNnT)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 7.3. Lacto-N-tetraose (LNT)
  • 7.4. 2'-Fucosyllactose (2'FL)
  • 7.5. 3'-Fucosyllactose (3'FL)
  • 7.6. 3'-Sialyllactose (3'SL)
  • 7.7. 6'-Sialyllactose (6'SL)
  • 7.8. Others

8. Global Human Milk Oligosaccharides Market - By Type

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Type segment
    • 8.1.2. Market attractiveness index, By Type segment
  • 8.2. Neutral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 8.3. Acidic
  • 8.4. Others

9. Global Human Milk Oligosaccharides Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 9.1.2. Market attractiveness index, By Application Segment
  • 9.2. Infant Formula*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 9.3. Dietary Supplements
  • 9.4. Functional Food and Beverages
  • 9.5. Others

10. Global Human Milk Oligosaccharides Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America*
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.5.7.
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

11. Global Human Milk Oligosaccharides Market - Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Elicityl SA
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medolac Laboratories
  • 12.3. Inbiose NV
  • 12.4. Glycosyn
  • 12.5. ZuChem
  • 12.6. Jennewein Biotechnologie Gmbh
  • 12.7. Glycom A/S
  • 12.8. Dextra Laboratories Limited
  • 12.9. DuPont Nutrition & Health
  • 12.10. Nestle Health Science
  • List not Exhaustive*

13. Global Human Milk Oligosaccharides Market - Premium Insights

14. Global Human Milk Oligosaccharides Market - DataM

  • 14.1. Appendix
  • 14.2. About us and services
  • 14.3. Contact us